NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I'm just a little suspicious:

1. How does the author know NWBO's otherwise unpublished accrual rate? ( I don't believe he does) (Regardless, it shows you how important it is for some immunology proponents to attempt slowing NWBO progress, or at least create a perception of slow progress. AF's prior false articles certainly must intend to interfere with NWBO accrual as well. Hmm, AF is a fan of Celldex as well. Notice a pattern?)

2. Roche is based in Switzerland.

3.

The epidermal growth factor receptor variant III (EGFRvIII) is a naturally occurring mutant of EGFR and is expressed on approximately 20% to 30% of GBMs. As it is not expressed on normal cells, it is an ideal therapeutic target. Rindopepimut is a peptide vaccine which elicits EGFRvIII-specific humoral and cellular immune responses. Phase I and II clinical trials have demonstrated significantly higher progression-free and overall survival times in vaccinated patients with EGFRvIII-expressing GBM tumors. -- Directly from the Celldex website.

Consequently, it takes the narrow targeting approach.

4. Etc.